A Phase 1 Study of NBTXR3 Activated by Radiotherapy With Concurrent Chemotherapy for Adenocarcinoma of the Esophagus
Latest Information Update: 24 May 2024
At a glance
- Drugs Capecitabine (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Hafnium oxide (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Adverse reactions
- Sponsors Nanobiotix
- 21 May 2024 According to a Nanobiotix media release,Dose escalation part ongoing,the company expected to complete dose escalation part and initiation of dose expansion part in this year. first data will be presented in 2025.
- 13 Nov 2023 According to a Nanobiotix media release, determination of RP2D in NSCLC trial, Completion of enrollment in Phase 1b dose expansion trial in pancreatic cancer, Initial Phase 1b/2 data in esophageal cancer data expected in 2024.
- 08 Nov 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2025.